Table 6.

Univariate and multivariate survival analysis (n = 231).

Characteristic		Univariate				Multivariate
	N	Event N	HR 1	95% CI 1	p-Value	Event N	HR 1	95% CI 1	p-Value
Age	227	40
<50			—	—
≥50			0.85	0.42, 1.74	0.7
Sex	227	40
Female			—	—
Male			0.90	0.48, 1.69	0.7
Tumor Site	226	40
Left			—	—
Right			1.01	0.48, 2.12	>0.9
Stage	223	40				30
I–II			—	—			—	—
III–IV			2.18	1.03, 4.60	0.040 *		1.82	0.58, 5.73	0.3
T Status	227	40
1–2			—	—
3–4			3.21	0.77, 13.3	0.11
x			†
Node Status	227	40				30
0			—	—			—	—
1			1.29	0.64, 2.61	0.5		0.79	0.27, 2.37	0.7
2			3.35	1.45, 7.72	0.005 **		1.97	0.62, 6.30	0.3
x			†
Metastatic Status	227	40
0			—	—
1			1.86	1.00, 3.48	0.051
x			†
Histological Grading	225	38				30
1–2			—	—			—	—
3–4			2.23	1.05, 4.71	0.036 *		1.27	0.51, 3.16	0.6
Lymphovascular Status	109	22
0			—	—
1			0.70	0.30, 1.65	0.4
Pathological Morphology	227	40
Adenocarcinoma			—	—
Mucinous Carcinoma			1.66	0.23, 12.1	0.6
TILs	189	33
High			—	—
Medium			0.85	0.38, 1.93	0.7
Low			2.29	0.95, 5.51	0.065
Hemoglobin level (g/dL)	220	40
<10			—	—
≥10			0.62	0.22, 1.79	0.4
Serum albumin (g/dL)	160	35
<3.5			—	—
>3.5			0.62	0.31, 1.25	0.2
ECOG	198	32				30
ECOG 0–1			—	—			—	—
ECOG 2			2.18	0.90, 5.27	0.083		1.70	0.64, 4.50	0.3
ECOG 3–4			4.60	1.98, 10.7	<0.001 ***		4.38	1.72, 11.2	0.002 **
BMI (kg/m2)	219	38
<18.5			—	—
18.5–22.9			0.87	0.41, 1.84	0.7
23–24.9			0.81	0.28, 2.29	0.7
≥25			0.73	0.26, 2.07	0.6
Microsatellite Instability Status	227	40
MSI			—	—
MSS			0.82	0.39, 1.73	0.6
BRAF Exon 15	227	40
Mutant			—	—
Wild-type			0.89	0.35, 2.28	0.8
MLH1 Methylation	227	40
Methylated			—	—
Unmethylated			0.96	0.13, 6.96	>0.9
Probable Lynch	227	40
No			—	—
Yes			1.25	0.55, 2.83	0.6

¹ HR = Hazard Ratio, CI = Confidence Interval; ^† Too small a number to analyse; TILs, Tumour-infiltrating lymphocytes; ECOG, Eastern Cooperative Oncology Group Performance Status; BMI, Body Mass Index; MSI, Microsatellite Instability; MSS, Microsatellite Stable; * p < 0.05; ** p < 0.01; *** p < 0.001.